AtriCure
ATRC | NASDAQ
$55.31
-$1.53 (-2.69%)
At close: Nov 16, 2026, 4:00 PM ET
$55.31
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
AtriCure Company Profile
Company profile explainedCompany Profile
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Key Executives
| Name | Position |
|---|---|
| Michael H. Carrel | Chief Executive Officer, President & Director |
| Angela L. Wirick | Chief Financial Officer |
| Douglas J. Seith | Chief Operating Officer |
| Karl S. Dahlquist CCEP | Chief Legal Officer |
| Justin J. Noznesky | Chief Marketing & Strategy Officer |
| Salvatore Privitera | Chief Technical Officer |
| Valerie Storch-Willhaus | Vice President of Corporate Marketing & Communications |
| Vinayak Doraiswamy | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 24, 2026 | 4 | Filing |
| Sep 14, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
AtriCure
| Country | United States |
| IPO Date | Aug 5, 2005 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,350 |
| CEO | Michael H. Carrel |
Contact Details
7555 Innovation Way Mason,
Ohio 45040 United States
Stock Details
| Ticker Symbol | ATRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001323885 |
| CUSIP Number | 04963C209 |
| ISIN Number | US04963C2098 |
| SIC Code | 3841 |
Recent News
- 8 days ago / seekingalpha.comAtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript
- 9 days ago / seekingalpha.comAtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- 13 days ago / benzinga.comAtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
- 13 days ago / seekingalpha.comAtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comWhat AtriCure (ATRC) Said on Its Q3 Earnings Call
- 13 days ago / zacks.comCompared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
- 13 days ago / zacks.comAtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
- 1 month ago / businesswire.comAtriCure to Announce Third Quarter 2026 Financial Results
- 2 months ago / zacks.comIs AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
- 2 months ago / zacks.comDo Options Traders Know Something About AtriCure Stock We Don't?
Add to Watchlist
Select watchlists to add or remove ATRC